摘要
Abstract
Objective To explore the adjuvant therapeutic effect and prognostic improvement of colchicine for stable coro-nary artery disease(SCAD).Methods A total of 100 SCAD patients admitted to Sichuan Provincial Corps Hospital of Chinese People's Armed Police Force from January 2022 to July 2023 were selected.According to different treatment methods,they were di-vided into a colchicine group and a control group,with 50 cases in each group.The control group received conventional treatment(such as statins,antiserum plate drugs,etc.),while the colchicine group received colchicine on the basis of conventional treatment.Both groups underwent a 12-month treatment period.After treatment,the survival rate,treatment effect,major adverse cardiovascular events(MACE),quality of life(QOL),and levels of serum inflammatory factor,such as interleukin-6(IL-6)and high-sensitivity C-re-active protein(hs-CRP),were compared between the two groups.Results After treatment,the total effective rate of the colchicine group was 91.84%and the score of the Short Form 36 Health Survey(SF-36)was(84.13±14.13),which was higher than 85.11%and(82.47±12.64)of the control group,but the difference were not statistically significant(P>0.05).After treatment,the inci-dence of MACE of the colchicine group was 6.00%,which was significantly lower than of the control group(20.00%),and the differ-ence was statistically significant(P<0.05);the levels of IL-6 and hs-CRP in the serum were(1.99±0.78)ng/L and(2.04±0.98)mg/L,respectively,which were significantly lower than those of the control group(2.48±1.32)ng/L and(4.30±1.21)mg/L,and the difference was statistically significant(P<0.05).Conclusions Colchicine has a significant adjuvant therapeutic ef-fect on SCAD and can reduce the incidence of MACE and the levels of IL-6 and hs-CRP in the serum of SCAD patients.关键词
秋水仙碱/稳定型冠心病/辅助治疗/心血管不良事件/炎症因子Key words
colchicine/stable coronary artery disease/adjuvant treatment/major adverse cardiovascular events/inflamma-tory factor分类
医药卫生
